AGILE THERAPEUTICS INC

agiletherapeutics.com

No Longer Reporting

The company has not filed an annual or quarterly report since its Q2 FY2024 10-Q, filed Aug 12, 2024. Its latest SEC filing is a SC 13G/A from Nov 13, 2024.

The sections below describe the company as of the FY2023 annual report.

What Did They Do?

Sold Twirla, a prescription hormonal contraceptive patch, for women seeking contraception.

How Did They Make Money?

Agile sold Twirla mainly to wholesale distributors and earned product revenue when customers received the product; discounts, rebates and other allowances reduced sales.

FY2023 revenue

Who Were Their Customers?

Its customers were primarily U.S. wholesale distributors; Twirla reached patients through retail and non-retail channels, including telemedicine and public health centers through Afaxys.

Did Revenues Turn Into Profits?

No. It lost $14.5M in FY2023.

Operating income, FY2023

−101% of revenue

▼ −62% (Loss) vs FY2022 (−$52.6M, −483%)

Net income, FY2023

−74% of revenue

▼ −43% (Loss) vs FY2022 (−$25.4M, −233%)

How Were They Changing?

Since the FY2023 annual report

Latest quarter: Q2 FY2024, the three months to Jun 30, 2024

Revenue: ▲ +1%; vs $5.5M in Q2 FY2023
Net income: ▲ +212% (Loss); vs −$3.8M in Q2 FY2023

Aug 26, 2024 Insud Pharma completed its acquisition of Agile Agile became an indirect subsidiary of Insud Pharma, and its common stock ceased to be publicly traded.

Partnership-led sales reach The earlier plan listed retail and specialty pharmacies, telemedicine, and government contracting; the later plan described expanding telemedicine through Nurx and non-retail reach through Afaxys.

Who Did They Compete With?

Competes with Organon, Mayne Pharmaceuticals, Allergan, Bayer, Viatris, Amneal, Sandoz, Glenmark, Lupin, Mylan, Aurobindo, Xiromed, Evofem, Mithra Pharmaceuticals, Population Council, and Dare Bioscience

Comments